CPRX

Catalyst Pharmaceuticals, Inc.

A Florida biopharma that targets rare diseases, Catalyst Pharmaceuticals sells three FDA-approved drugs: FIRDAPSE for Lambert-Eaton myasthenic syndrome, a rare nerve-muscle disorder; AGAMREE for Duchenne muscular dystrophy; and FYCOMPA for epilepsy. It began in 2002 working on addiction therapies before pivoting to rare neuromuscular conditions, carving out a niche in medicines with few existing options.